Winrevair (sotatercept-csrk) / BMS, Merck (MSD) - LARVOL DELTA

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results… (Merck (MSD) Press Release) - "Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX): KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million; WINREVAIR Sales Were $1.4 Billion; CAPVAXIVE Sales Were $759 Million; GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decline Both Nominally and ex-FX)."

Sales • Anal Carcinoma • Bladder Cancer • Cholangiocarcinoma • Colorectal Cancer • Cutaneous Melanoma • Endometrial Cancer • Gastroesophageal Junction Adenocarcinoma • HER2 Negative Breast Cancer • Hormone Receptor Negative Breast Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Merkel Cell Carcinoma • Microsatellite Instability • Neuroendocrine Carcinoma • Oropharyngeal Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • Vaginal Cancer

New Targets, New Trials in PAH: A New Hope? (ISHLT 2026) - "This talk will explore emerging therapeutic targets in pulmonary arterial hypertension (PAH), such as drugs targeting the BMPR2 and activin signaling pathways. It will highlight novel agents such as Sotatercept, Seralutinib, and Ralinepag, emphasizing how these therapies may redefine and reshape the future treatment landscape of PAH."

Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

A Systems Biology Framework Uncovers Multi-Level Genetic Regulation of Dizziness/vertigo Through eQTL-GWAS Integration and Single-Cell Analysis. (PubMed, Int J Neurosci) - "Interaction network analysis positioned these genes as major hubs, and DrugBank screening identified Sotatercept as a promising candidate targeting ACVR2A. This integrative analysis links gene expres-sion regulation to dizziness/vertigo across neuroimmune and metabolic systems. The findings uncover coordinated molecular pathways underlying disease susceptibility and highlight novel therapeutic targets, providing a foundation for precision treatment strate-gies."

Journal • CNS Disorders • Otorhinolaryngology • Vertigo • ACVR2A • CD4 • COL7A1 • PLTP • TERC

Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects. (PubMed, Biomolecules) - "Although vasodilators targeting the endothelin, nitric oxide, and prostacyclin pathways remain the therapeutic backbone, newer agents-including the activin signal inhibitor sotatercept and inhaled treprostinil-have expanded treatment options. Immune-targeted therapies such as glucocorticoids, cyclophosphamide, mycophenolate mofetil, rituximab, and IL-6 receptor inhibitors may benefit inflammation-dominant PAH phenotypes, while fibrotic phenotypes continue to demonstrate limited responsiveness...Despite these developments, substantial unmet needs remain, including the absence of disease-specific therapeutic strategies, limited biomarker integration into clinical practice, and a scarcity of large, well-designed trials targeting individual CTD subtypes. Addressing these gaps will be essential for improving prognosis in patients with CTD-PAH."

Journal • Review • Cardiovascular • Fibrosis • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • IL6 • NPPB

Exploring the Prognostic Role of PETCOand VO/Work Rate Slope for Risk SubStratification in Patients with Pulmonary Arterial Hypertension at Intermediate Risk: A Pilot CPET Study (IWLH 2026) - "This study examines whether PETCO₂ and VO₂/WR-derived indices provide incremental prognostic value beyond established CPET markers in PAH. If validated, these physiological variables may refine risk stratification, deepen understanding of exercise limitation and support personalised management in the Sotatercept era."

Biomarker • Clinical • Late-breaking abstract • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

SOFAPI: Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH (clinicaltrials.gov) - P1/2 | N=15 | Not yet recruiting | Sponsor: University Hospital, Brest

New P1/2 trial • Cardiovascular • Congestive Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Sotatercept in Pulmonary Arterial Hypertension: Molecular Mechanisms, Clinical Evidence, and Emerging Role in Reverse Remodelling. (PubMed, Int J Mol Sci) - "Evidence from pivotal phase II and III trials-PULSAR, STELLAR, ZENITH, and HYPERION-demonstrates that sotatercept significantly improves exercise capacity, haemodynamics, and risk status when added to background therapy. This review summarises the molecular mechanisms underlying sotatercept's therapeutic effects, synthesises the current clinical evidence, and discusses its emerging role as a disease-modifying agent capable of promoting reverse pulmonary vascular remodelling within contemporary PAH management."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • TGFB1

Sotatercept May Influence Primary Graft Dysfunction Scores in Pulmonary Arterial Hypertension Patients Undergoing Lung Transplant (ISHLT 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases • Transplantation

Efficacy and Safety of Sotatercept in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Indian Heart J) - "Sotatercept markedly reduces clinical worsening and improves multidimensional outcomes in PAH with an acceptable safety profile, supporting its role as a disease-modifying therapy."

Journal • Retrospective data • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

TITLE: THE EFFECT OF SOTATERCEPT IN PATIENTS OF PULMONARY ARTERY HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Retrospective data • Review • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension

Multidimensional Response to Sotatercept Therapy in Pulmonary Arterial Hypertension: A Real-World Experience (ISHLT 2026) - "Abstract is embargoed at this time."

Clinical • Real-world • Real-world evidence • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

Efficacy And Safety Of Sotatercept In Combined Post- And Pre-capillary Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction: Results From The Phase 2 Cadence Trial (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Late-breaking abstract • P2 data • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Sotatercept: from clinical trials to real world data & pearls from practice (PVRI 2026) - No abstract available

Clinical • Real-world • Real-world evidence

Vascular remodeling effects: how else does sotatercept work? (PVRI 2026) - No abstract available

SESSION 1: Sotatercept: from clinical trials to emerging insights (PVRI 2026) - No abstract available

Clinical

Beyond sotatercept, what is the future of TGFb/activin signaling in PAH? (PVRI 2026) - No abstract available

A TALE OF TWO OBSTRUCTIONS: CARDIAC TAMPONADE AFTER INITIATION OF SOTATERCEPT IN PULMONARY ARTERIAL HYPERTENSION (ACC 2026) - "Abstract is embargoed at this time."

Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

Eighteen Months of Therapeutic Progress: Our Journey with Sotatercept (ISHLT 2026) - "Abstract is embargoed at this time."

Cardiovascular

IMPACT OF SOTATERCEPT ON FUNCTIONAL AND HEMODYNAMIC OUTCOMES IN PULMONARY ARTERIAL HYPERTENSION- A SYSTEMATIC REVIEW AND META-ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Retrospective data • Review • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

SuMILE: A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy (clinicaltrials.gov) - P4 | N=36 | Recruiting | Sponsor: Kazuya Hosokawa

New P4 trial • Cardiovascular • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

OFF-LABEL SOTATERCEPT IN HIGH-RISK PULMONARY HYPERTENSION WITH LIVER DISEASE AND LIMITED THERAPEUTIC OPTIONS (ACC 2026) - "Abstract is embargoed at this time."

Cardiovascular • Hepatology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Change in Hemoglobin (Hgb) vs Improved Exercise Capacity in Sotatercept-Treated Patients with Pulmonary Arterial Hypertension (PAH) in the Phase 3 STELLAR Trial (ISHLT 2026) - "Abstract is embargoed at this time."

Clinical • P3 data • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

Sotatercept impairs right ventricular function: insights from multi-center preclinical studies (PVRI 2026) - No abstract available

Preclinical

Sotatercept for the Treatment of Portopulmonary Hypertension (ISHLT 2026) - "Abstract is embargoed at this time."

Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Phase 3, Open-Label Multicenter Study of Sotatercept in Japanese Participants With Pulmonary Arterial Hypertension. (PubMed, JACC Asia) - P3 | "In this study of Japanese participants with PAH, improvements in pulmonary vascular resistance and 6-minute walk distance were observed, consistent with the pivotal phase 3 STELLAR (A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension [MK-7692-003/A011-11]) trial. These data suggest that sotatercept may be an important treatment option for Japanese patients with PAH. (A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension [PAH] Participants [MK-7962-020], NCT05818137; Japan Registry of Clinical Trials [jRCT2031230046])."

Clinical • Journal • P3 data • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases